Author: Sablerolles, Roos S G; Hogenhuis, Freija E F; Lafeber, Melvin; van de Loo, Bob P A; Borgsteede, Sander D; Boersma, Eric; Versmissen, Jorie; van der Kuy, Hugo M
Title: COvid MEdicaTion (COMET) study: protocol for a cohort study Cord-id: icjt8bbw Document date: 2020_6_25
ID: icjt8bbw
Snippet: Various theories about drugs such as ACE inhibitors or angiotensin II receptor blockers (ARBs) in relation to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clinical outcomes of COVID-19 are circulating in both mainstream media and medical literature. These are based on the fact that ACE2 facilitates SARS-CoV-2 cell invasion via binding of a viral spike protein to ACE2. However, the effect of ACE inhibitors, ARBs and other drugs on ACE2 is unclear and all theories are based on
Document: Various theories about drugs such as ACE inhibitors or angiotensin II receptor blockers (ARBs) in relation to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clinical outcomes of COVID-19 are circulating in both mainstream media and medical literature. These are based on the fact that ACE2 facilitates SARS-CoV-2 cell invasion via binding of a viral spike protein to ACE2. However, the effect of ACE inhibitors, ARBs and other drugs on ACE2 is unclear and all theories are based on conflicting evidence mainly from animal studies. Therefore, clinical evidence is urgently needed. The aim of this study is to investigate the relationship between use of these drugs on clinical outcome of patients with COVID-19. Patients will be included from several hospitals in Europe. Data will be collected in a user-friendly database (Digitalis) on an external server. Analyses will be adjusted for sex, age and presence of cardiovascular disease, hypertension and diabetes. These results will enable more rational choices for randomised controlled trials for preventive and therapeutic strategies in COVID-19.
Search related documents:
Co phrase search for related documents- ace inhibitor and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- ace inhibitor and admission icu: 1, 2, 3, 4, 5
- ace inhibitor and logistic course: 1
- ace inhibitor and logistic regression: 1, 2, 3, 4, 5, 6, 7
- ace inhibitor and lung injury: 1, 2, 3, 4
- acute ards respiratory distress syndrome and admission hospital admission: 1
- acute ards respiratory distress syndrome and admission icu: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and admission icu icu: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute ards respiratory distress syndrome and local vascular leakage: 1
- acute ards respiratory distress syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lung injury contribute: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome show and lung injury: 1
- acute sars cov respiratory syndrome coronavirus and admission hospital admission: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute sars cov respiratory syndrome coronavirus and admission icu: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars cov respiratory syndrome coronavirus and admission icu icu: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute sars cov respiratory syndrome coronavirus and local vascular leakage: 1
- acute sars cov respiratory syndrome coronavirus and logistic course: 1
- acute sars cov respiratory syndrome coronavirus and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date